Etoposide liver toxicity
WebSep 21, 2016 · To investigate the effect of organ function on total and free etoposide pharmacokinetics and hematologic toxicity. PATIENTS AND METHODS Seventy-two patients who received single-agent intravenous (i.v.) etoposide over 5 or 8 days (total dose, 500 mg/m2) were studied. WebMay 5, 2024 · Etoposide: 1.5-3.0 mg/dL or SGOT > 180 units = Administer 50% dosage. Decreased albumin increases unbound drug concentration and increases hematologic toxic effects. Renal. CrCI = 10-50 mL/min = Administer 75% of dosage; CrCI = < 10 mL/min = Administer 50% of dosage; Hemodialysis = Administer 50% of dosage : Fludarabine
Etoposide liver toxicity
Did you know?
WebEtoposide is a podophyllotoxin deriverative with activity against a wide variety of malignancies. It is also used in many clinical conditions in which renal or hepatic function is impaired. To establish a basis for making initial dose adjustments in patients with renal or hepatic dysfunction, the clinical pharmacology (e.g., absorption, distribution, protein … WebDose adjustment for baseline liver or renal dysfunction: Each carboplatin dose should be calculated based upon renal function by use of the Calvert formula.* A lower starting dose of etoposide may be needed for patients with renal or liver impairment. [2] ... Suggested dose modifications for toxicity:
http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Etoposide_monograph.pdf WebPredicting etoposide toxicity: relationship to organ function and protein binding. Increased hematologic toxicity after etoposide in patients with abnormal organ …
WebApr 14, 2024 · Figure 4. atm mutation suppresses the toxic response to etoposide or H 2 O 2 exposure (A) Treatment scheme for exposure to etoposide and H 2 O 2. ( B ) The percent of WT, atm −/− and tp53 −/− embryos that have morphological defects or lethality in response to etoposide or H 2 O 2 . WebBleomycin, etoposide, and cisplatin are classified as irritants. Cisplatin can cause significant tissue damage; avoid extravasation. ... Dose adjustment for baseline liver or renal dysfunction: Bleomycin should not be administered in patients with a baseline creatinine >2.0 mg/dL. A lower initial dose of cisplatin or etoposide may be needed for ...
WebTwo cases of toxic hepatitis developing in patients receiving high-dose etoposide (VP-16-213) for refractory germinal neoplasms are described. Each patient received a total cumulative dose of at least 6800 mg/m2. Liver function abnormalities, including hyperbilirubinemia, elevated transaminases, and …
WebSep 15, 2024 · Liver injury from carboplatin is extremely rare. There is likely to be cross sensitivity to liver toxicities of the various platinum coordination complexes and … cybersoft philippinesWebJul 1, 2005 · Early reports described significant toxicity when full-dose bolus 5-FU was administered to patients with liver metastases and jaundice, leading to the recommendation that 5-FU be withheld in patients with serum bilirubin concentrations greater than 5 … cybersoft operating corporationWebEtoposide is a semisynthetic derivative of the podophyllotoxins, an epipodophyllotoxin. It inhibits DNA topoisomerase II, thereby inhibiting DNA synthesis. Etoposide is cell cycle … cybersoft integrated geoinformatics incWebSep 12, 2024 · Uncommon but potential severe adverse events include severe neutropenia, bleeding, peripheral neuropathy, pulmonary toxicity, hypersensitivity reactions and embryo-fetal toxicity. Hepatotoxicity Despite being cytotoxic for cancer cells and metabolized actively by the liver, the vinca alkaloids have only rarely been associated with … cybersoft llcWebEtoposide DRUG NAME: Etoposide SYNONYM(S): VP-161 COMMON TRADE NAME: VEPESID®, ... syndrome of liver and renal failure, pulmonary deterioration, thrombocytopenia and ascites has been associated with ... monitor toxicity closely high dose cyclosporine with oral etoposide. 14. increase in plasma level in etoposide . … cybersoft incWebJul 25, 2024 · Courses of therapy may be repeated at 3 to 4 week intervals, after adequate recovery from toxicity. Monitoring: Patients should be frequently observed for myelosuppression both during and after therapy. Dose-limiting bone marrow suppression is the most significant toxicity. cybersoft north america incWebPotentiation of preexisting liver disease, especially viral hepatitis. Altered hepatic drug metabolism due to underlying liver disease can result in higher or more persistent drug levels, thereby causing increased systemic toxicity (particularly myelosuppression) or worsening of liver function because of chemotherapy-induced hepatotoxicity. cybersoft operating corp